Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination

• Published in: The Journal of infectious diseases Vol. 226; no. 8; pp. 1391 - 1395
• Main Authors: Kurahashi, Yukiya, Furukawa, Koichi, Sutandhio, Silvia, Tjan, Lidya Handayani, Iwata, Sachiyo, Sano, Shigeru, Tohma, Yoshiki, Ohkita, Hiroyuki, Nakamura, Sachiko, Nishimura, Mitsuhiro, Arii, Jun, Kiriu, Tatsunori, Yamamoto, Masatsugu, Nagano, Tatsuya, Nishimura, Yoshihiro, Mori, Yasuko
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 17.10.2022
• Subjects: Brief Report; Coronaviruses; COVID-19; mRNA; Severe acute respiratory syndrome coronavirus 2; Vaccination; COVID-19; convalescent; SARS-CoV-2; omicron; cross-neutralizing antibody
• ISSN: 0022-1899; 1537-6613; 1537-6613
• DOI: 10.1093/infdis/jiac178

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron. We demonstrated that cross-neutralizing activity against omicron in COVID-19 convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination.